Alumni
-
Arthritis drug could be first to stop heart valve calcification
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJun. 13, 2017
-
BME alumna honored with state STEM advocate award
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 29, 2017
-
Student rocketeers earn second place in NASA contest
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 12, 2017
-
Dean presents 2017 engineering faculty, staff awards
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 10, 2017
-
Galloway, the Wond’ry team design wrist-saving, wick-installing device for Thistle Farms
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 8, 2017
-
Six engineering faculty named to endowed chairs
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 8, 2017
-
Grand Stair dedicated in honor of alumni Ed and Sue Clark
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 4, 2017
-
Two engineering seniors to explore the world as Keegan Traveling Fellows
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 2, 2017
-
Engineering professors offer a free Senior Day seminar
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 1, 2017
-
Dean Fauchet reappointed for five-year term
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreApr. 27, 2017